Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 28
Filter
1.
Scand J Gastroenterol ; 59(3): 333-343, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38018772

ABSTRACT

The prognostic role of the Age-Adjusted Charlson Comorbidity Index (ACCI) in hilar cholangiocarcinoma patients undergoing laparoscopic resection is unclear. To evaluate ACCI's effect on overall survival (OS) and recurrence-free survival (RFS), we gathered data from 136 patients who underwent laparoscopic resection for hilar cholangiocarcinoma at Zhengzhou University People's Hospital between 1 June 2018 and 1 June 2022. ACCI scores were categorized into high ACCI (ACCI > 4.0) and low ACCI (ACCI ≤ 4.0) groups. We examined ACCI's association with OS and RFS using Cox regression analyses and developed an ACCI-based nomogram for survival prediction. Our analysis revealed that higher ACCI scores (ACCI > 4.0) (HR = 2.14, 95%CI: 1.37-3.34) were identified as an independent risk factor significantly affecting both OS and RFS in postoperative patients with hilar cholangiocarcinoma (p < 0.05). TNM stage III-IV (HR = 7.42, 95%CI: 3.11-17.68), not undergoing R0 resection (HR = 1.58, 95%CI: 1.01-2.46), hemorrhage quantity > 350 mL (HR = 1.92, 95%CI: 1.24-2.97), and not receiving chemotherapy (HR = 1.89, 95%CI: 1.21-2.95) were also independent risk factors for OS. The ACCI-based nomogram accurately predicted the 1-, 2-, and 3-year OS rates, with Area Under the Curve (AUC) values of 0.818, 0.844, and 0.924, respectively. Calibration curves confirmed the nomogram's accuracy, and decision curve analysis highlighted its superior predictive performance. These findings suggest that a higher ACCI is associated with a worse prognosis in patients undergoing laparoscopic resection for hilar cholangiocarcinoma. The ACCI-based nomogram could aid clinicians in making accurate predictions about patient survival and facilitate individualized treatment planning.


Subject(s)
Bile Duct Neoplasms , Cholangiocarcinoma , Klatskin Tumor , Laparoscopy , Humans , Prognosis , Klatskin Tumor/surgery , Age Factors , Bile Duct Neoplasms/surgery , Comorbidity , Retrospective Studies , Cholangiocarcinoma/surgery
2.
Front Surg ; 9: 814540, 2022.
Article in English | MEDLINE | ID: mdl-35711703

ABSTRACT

Background: It is still controversial whether preoperative oral carbohydrate (POC) should be applied to patients with type 2 diabetes mellitus (T2DM) in the enhanced recovery after surgery (ERAS) protocol. There is no relevant consensus or indicators to provide guidance as to whether T2DM patients should take POC. Methods: In total, 164 T2DM patients who underwent laparoscopic hepatectomy were analyzed. According to the level of blood free fatty acids (FFAs) and whether the patients received POC, the patients were divided into 6 groups: the low FFA carbohydrate group (LFFAC group), low FFA fasting water group (LFFAF group), medium FFA carbohydrate group (MFFAC group), medium FFA fasting water group (MFFAF group), high FFA carbohydrate group (HFFAC group) and high FFA fasting water group (HFFAF group). Results: Patients with low FFA levels showed better perioperative blood glucose control and a lower incidence of postoperative complications than those in the medium and high FFA groups, especially when patients received POC. Further analyses revealed that the postoperative plasma concentrations of IL-6 and TNF-α were significantly decreased in the POC group compared with the fasting water group, except for patients with high FFA levels. Receiver operating characteristic (ROC) curve analysis revealed that when the FFA concentration was higher than 0.745 mmol/L, the risk of poor blood glucose control during the perioperative period was increased. Conclusions: FFAs have clinical guiding significance for the application of POC in patients with T2DM under ERAS administration. T2DM patients with low FFAs are more suitable for receiving POC.

3.
RSC Adv ; 11(53): 33354-33360, 2021 Oct 08.
Article in English | MEDLINE | ID: mdl-35497557

ABSTRACT

In this study, a polysilane-modified graphene oxide (GO) and carbon nanotube (CNT) nanocomposite (GO/CNTs-Si) was prepared as a thermal conductive nanofiller to enhance the thermal and mechanical properties of silicone rubber composites. By γ-ray-radiation 3-methacryloxypropyltrimethoxy silane (MPTMS) was polymerized on the surface of GO and CNTs to improve the interfacial interaction between the GO/CNTs-Si and SR matrix. FTIR characterization results demonstrated that polysilane modified the GO/CNTs successfully. The pristine GO/CNTs and resultant GO/CNTs-Si were individually incorporated into α,ω-dihydroxypolydimethylsiloxane to vulcanize SR composites. Compared with SR-GO/CNTs, SR-GO/CNT-Si exhibited better mechanical and thermal performance. Moreover, the time-dependent complex modulus of SR-GO/CNTs-Si was much higher than that of SR-GO/CNTs, which indicates longer service time and more stable performance. In terms of electronic packaging, SR-GO/CNTs exhibited better performance than the 1180B counterpart. The low value of warpage of chip packaged by SR-GO/CNTs implied that SR-GO/CNTs-Si could have potential application as the thermal interface electronic packaging material.

4.
J Surg Oncol ; 123(1): 196-203, 2021 Jan.
Article in English | MEDLINE | ID: mdl-32996132

ABSTRACT

BACKGROUND: Although pancreatic neuroendocrine tumors (PNETs) are considered indolent tumors, nearly half of cases metastasize to the liver, which can be lethal. However, effective indicators to predict aggressive behavior have not been well-established. METHODS: In the current study, we explored the prognostic significance of tumor budding in Grade 1-2 PNETs. Hematoxylin-eosin and immunohistochemically stained slides of surgically removed Grade 1-2 PNETs were evaluated. RESULTS: Tumor budding, a histomorphological parameter that corresponds to single cells or small cell clusters (<5 cells), was classified as low (0-10 buds) and high (>10 buds) grade. We observed that tumor budding was correlated with aggressive histopathological parameters, such as T stage, lymph node status, metastasis, and vascular invasion (p < .05). Univariate and multivariate analyses showed that high-grade budding was an independent predictive factor for postoperative liver metastasis (p = .012). Moreover, Grade 1-2 PNETs with high-grade budding was associated with worse overall survival and disease-free survival (p = .0015 and p = .0041, respectively). CONCLUSIONS: We conclude that tumor budding may serve as a valuable parameter in the risk stratification of postoperative liver metastasis and that incorporating tumor budding into histopathological reports may aid in appropriate clinical management.


Subject(s)
Liver Neoplasms/secondary , Neuroendocrine Tumors/pathology , Pancreatic Neoplasms/pathology , Adolescent , Adult , Aged , Aged, 80 and over , Female , Follow-Up Studies , Humans , Liver Neoplasms/surgery , Male , Middle Aged , Neuroendocrine Tumors/surgery , Pancreatic Neoplasms/surgery , Postoperative Period , Predictive Value of Tests , Survival Rate , Young Adult
5.
Materials (Basel) ; 11(11)2018 Oct 31.
Article in English | MEDLINE | ID: mdl-30384443

ABSTRACT

A facile and environmentally friendly method is proposed to prepare reduced graphene oxide⁻nickel (RGO⁻Ni) nanocomposites using γ-ray irradiation. Graphene oxide (GO) and Ni2+ are reduced by the electrons which originated from the gamma radiolysis of H2O. The structure and morphology of the obtained RGO⁻Ni nanocomposites were analyzed using X-ray diffraction (XRD) and Raman spectroscopy. The results show that Ni nanoparticles were dispersed uniformly on the surface of the RGO nanosheets. As expected, the combination of RGO nanosheets and Ni nanoparticles improved the electromagnetic wave absorption because of the better impedance matching. RGO⁻Ni nanocomposites exhibited efficient electromagnetic wave absorption performance. The minimum reflection loss (RL) of RGO⁻Ni reached -24.8 dB, and the highest effective absorption bandwidth was up to 6.9 GHz (RL < -10 dB) with a layer thickness of 9 mm.

6.
Pathol Res Pract ; 214(9): 1309-1314, 2018 Sep.
Article in English | MEDLINE | ID: mdl-30029936

ABSTRACT

This study was to test hypotheses that indoleamine 2, 3-dioxygenase and B7-H1 expressions can be used as prognostic markers in human pancreatic carcinoma (PC). Ninety-five patients were recruited who had undergone radical surgical resection for PC. IDO and B7-H1 expressions in PC tissue specimens were evaluated by immunohistochemistry (IHC) techniques. The clinical and pathological features of these specimens were analyzed. IDO positive, B7-H1 positive, and combined IDO/B7-H1 positive tumors exhibited significant correlations with lymphocytic infiltration, perineural invasion, TNM status, and pathologic grade (p < .05), which tended to show strong correlations with malignant progression of PC. Also, IDO correlated with diabetes mellitus (DM) and HAD scale and B7-H1 correlated with smoke (p < .05). In addition, the correlation analysis indicated that IDO had a positive correlation with B7-H1 (p < .05). Moreover, the results showed that a combination of IDO and B7-H1 expressions could serve as independent prognostic marker after adjusting by Cox proportional hazards regression models (p < .05). IDO and B7-H1 expressions were observed in patient with PC tissues and are important markers for PC malignant progression. A combination of IDO and B7-H1 expression can be served as an independent prognostic marker for PC.


Subject(s)
B7-H1 Antigen/biosynthesis , Biomarkers, Tumor/analysis , Indoleamine-Pyrrole 2,3,-Dioxygenase/biosynthesis , Pancreatic Neoplasms/pathology , Adolescent , Adult , Aged , B7-H1 Antigen/analysis , Female , Follow-Up Studies , Humans , Indoleamine-Pyrrole 2,3,-Dioxygenase/analysis , Kaplan-Meier Estimate , Male , Middle Aged , Pancreatic Neoplasms/mortality , Prognosis , Proportional Hazards Models , Retrospective Studies , Young Adult , Pancreatic Neoplasms
7.
Surg Laparosc Endosc Percutan Tech ; 26(3): e69-72, 2016 Jun.
Article in English | MEDLINE | ID: mdl-27258919

ABSTRACT

OBJECTIVE: To evaluate the feasibility and safety of laparoscopic liver resection in obese patients, we compared the operative outcomes between obese and nonobese patients, also between laparoscopic liver resection and open liver resection of obese and nonobese patients. MATERIALS AND METHODS: A total of 86 patients suffering from liver resection in our department from January 2013 to December 2014 were divided into 3 groups: the obese patients group for laparoscopic liver resection, the nonobese patients group for laparoscopic liver resection and the obese patients group for open liver resection. Characteristics and clinic data of 3 groups were studied. RESULTS: Characteristics of patients and clinic data were equivalent between the 3 groups. The groups were well matched in age, sex distribution, and liver function (P>0.05). There were no significant differences in the operative time, estimated blood loss, time to oral intake, and postoperative hospital stay in the 3 groups. Tumor diameter of laparoscopic liver resection groups in obese patients was smaller than open liver resections groups in obese patients (P<0.05), but there were no obvious difference of tumor diameter in the laparoscopic liver resection groups of the obese patients and the nonobese patients. CONCLUSIONS: Obesity should not be seen as a contraindication for laparoscopic liver resection, which is a safe and feasible procedure for obese patients.


Subject(s)
Carcinoma, Hepatocellular/surgery , Hemangioma, Cavernous/surgery , Laparoscopy/methods , Liver Neoplasms/surgery , Obesity/complications , Blood Loss, Surgical , Feasibility Studies , Female , Humans , Length of Stay , Male , Middle Aged , Operative Time , Retrospective Studies , Treatment Outcome
8.
J Laparoendosc Adv Surg Tech A ; 26(7): 524-30, 2016 Jul.
Article in English | MEDLINE | ID: mdl-27064936

ABSTRACT

BACKGROUND: In the recent years, laparoscopic splenectomy and esophagogastric devascularization (LSD) for liver cirrhosis and portal hypertension rapidly gained the interest of hepatobiliary surgeons due to its minimal invasion. This study aimed to gather and analyze available data from the observational studies that have compared LSD and open splenectomy and esophagogastric devascularization (OSD) for liver cirrhosis and portal hypertension. MATERIALS AND METHODS: All the studies comparing LSD and OSD for liver cirrhosis and portal hypertension were searched on the available databases, including the Cochrane Central Register of Controlled Trials, Medline, Science Citation Index, EMBASE, China National Knowledge Infrastructure, Wanfang Database, and China Biomedical Database. Data were analyzed using Review Manager software version 5.0. RESULTS: After the literature search, a total of 17 studies were included in the meta-analysis, which involved 1093 patients: 552 in the laparoscopic group and 541 in the open group. The laparoscopic group was shown to have a lower overall postoperative complication rate (0.43; 95% confidence interval [CI; 0.29-0.64]) than the open group (P < .0001), which was not associated with heterogeneity between the studies. The laparoscopic group was shown to have a lower intraoperative blood loss (-320.62; 95% CI [-552.35 to -88.9]), shorter time of oral intake (-29.08 hours; 95% CI [-35.28 to -22.88]), and shorter hospital stay (95% CI [-6.19 to -2.19]) than those of the open group (P < .00001). The operative time of the laparoscopic group was 42.16 minutes longer (95% CI [32.20-52.11]) compared with the open group (P < .00001). There was no significant difference of hospitalization costs between the studies. CONCLUSION: This meta-analysis demonstrated that laparoscopic left lateral resection is a safe and feasible option associated with a reduced overall complication rate. The current evidence suggested that it could be performed routinely in liver centers.


Subject(s)
Esophageal and Gastric Varices/surgery , Hypertension, Portal/surgery , Liver Cirrhosis/surgery , Blood Loss, Surgical , China , Esophageal and Gastric Varices/complications , Humans , Hypertension, Portal/complications , Laparoscopy , Length of Stay , Liver Cirrhosis/complications , Minimally Invasive Surgical Procedures , Operative Time , Postoperative Complications , Splenectomy , Vascular Surgical Procedures
9.
Mol Med Rep ; 13(1): 237-42, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26572166

ABSTRACT

The expression of Yes-associated protein (YAP) has been reported to be dysregulated in pancreatic cancer. However, its contributions to tumor formation and progression remain to be elucidated. The present study demonstrated that YAP overexpression promoted the epithelial­mesenchymal transition (EMT) in a manner associated with pancreatic cancer invasion in vitro. RNA interference­mediated silencing of YAP attenuated cell invasion in vitro. Mechanistically, the present study demonstrated that YAP overexpression fosters pancreatic cancer progression by inducing the EMT in pancreatic cancer cells by activating the AKT cascade, which can counteract the effect of gemcitabine. These data suggested that the YAP acts synergistically to promote pancreatic cancer progression by hyperactivation of AKT signaling. The present study revealed YAP as a potential therapeutic target for pancreatic cancer and a biomarker for predicting gemcitabine treatment response.


Subject(s)
Adaptor Proteins, Signal Transducing/metabolism , Drug Resistance, Neoplasm , Epithelial-Mesenchymal Transition , Pancreatic Neoplasms/pathology , Phosphoproteins/metabolism , Cell Line, Tumor , Deoxycytidine/analogs & derivatives , Deoxycytidine/pharmacology , Disease Progression , Drug Resistance, Neoplasm/drug effects , Enzyme Activation/drug effects , Epithelial-Mesenchymal Transition/drug effects , Humans , Neoplasm Invasiveness , Pancreatic Neoplasms/enzymology , Phenotype , Proto-Oncogene Proteins c-akt/metabolism , Signal Transduction/drug effects , Transcription Factors , Up-Regulation/drug effects , YAP-Signaling Proteins , Gemcitabine
10.
Surg Laparosc Endosc Percutan Tech ; 25(5): e145-7, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26429056

ABSTRACT

OBJECTIVE: To evaluate the feasibility and safety of laparoscopic versus open resection for liver cavernous hemangioma (LCH). MATERIALS AND METHODS: A total of 131 patients suffering from LCH operated in our department between January 2013 and December 2014 were divided into 2 groups: 31 for laparoscopic liver resection (LR) and 100 for open liver resection (OR). RESULTS: Age, sex, presence or absence of chronic liver disease, tumor size, tumor location, type of resection, estimated intraoperative blood loss, operative time, length of postoperative hospital stay, morbidity, and mortality were equivalent between the 2 groups. There were no significant differences in estimated intraoperative blood loss between the LR and OR groups. The operation time of the LR group was longer than the OR group and the hospitalization expenses less than the OR group. However, the time of postoperative hospital stay and time of oral intake were shorter in the LR group than the OR group. The tumor of the LR group was smaller than the OR group. In liver function, alanine aminotransferase after operation of the LR group was lower than the OR group, the same as aspartate transaminase after operation. But there were no significant differences in total bilirubin after operation. CONCLUSIONS: Laparoscopic resection for LCH is a safe and feasible procedure as OR.


Subject(s)
Hemangioma, Cavernous/surgery , Hepatectomy/methods , Laparoscopy/methods , Laparotomy/methods , Liver Neoplasms/surgery , Female , Follow-Up Studies , Hemangioma, Cavernous/diagnosis , Humans , Liver Neoplasms/diagnosis , Male , Middle Aged , Retrospective Studies , Time Factors , Tomography, X-Ray Computed , Treatment Outcome
11.
Tumour Biol ; 35(9): 9023-6, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24906606

ABSTRACT

Recently, many researchers have reported that the genetic polymorphisms of CYP2C19 may account for the interpatient variability of the clinical course in cancers including primary liver cancer (PLC). Besides the genetic polymorphisms of CYP2C19, hepatitis viruses (HV, including HAV, HBV, HCV, HDV, HEV, especially HBV and/or HCV) also account for the interpatient variability of the clinical course in PLC. This research covered the above two factors and divided the patients with PLC into two groups (one group with HBV infection and another without any HV infection) to find out whether the genetic polymorphisms of CYP2C19 have different effects in the progressing of PLC in different groups of patients. Eight hundred sixty-four cancer-free Han people (controls, named group 1), 207 Han PLC patients with HBV infection (group 2), and 55 Han PLC patients without any HV infection (group 3) were involved in this study. A wild-type allele (CYP2C19*1) and two mutated alleles (CYP2C19*2 and CYP2C19*3) were identified. The frequencies of the mutant alleles and genotypes were then compared with each other. The frequencies of the homozygous and heterozygous variant genotypes (*2/*2, *2/*3, *3/*3) in group 3 (25.5 %) were significantly higher than those in other groups (11.9 % in group 1 and 13.5 % in group 2, P = 0.014, 95 % confidence interval (CI)). The differences were statistically significant between group 1 and group 3 (P = 0.004, 95 % CI), but they were not statistically significant between group 1 and group 2 (P = 0.527, 95 % CI). Thus, we conclude that people which were not infected with HV but with the homozygous or heterozygous variant genotypes (*2/*2, *2/*3, *3/*3) of CYP2C19 may have higher possibilities of getting PLC than people with other allelic genotypes (*1/*1, *1/*2, *1/*3) (odds ratio (OR) = 2.523, 95 % CI = 1.329 ~ 4.788). However, in patients with HBV infection, the genetic polymorphisms of CYP2C19 did not seem to be an important factor in the risk of developing PLC (OR = 1.156, 95 % CI = 0.738 ~ 1.810).


Subject(s)
Cytochrome P-450 CYP2C19/genetics , Genetic Predisposition to Disease/genetics , Liver Neoplasms/genetics , Polymorphism, Genetic , Adult , Aged , Asian People/genetics , China , Female , Gene Frequency , Genetic Predisposition to Disease/ethnology , Genotype , Hepatitis Viruses/physiology , Hepatitis, Viral, Human/ethnology , Hepatitis, Viral, Human/genetics , Hepatitis, Viral, Human/virology , Host-Pathogen Interactions , Humans , Liver Neoplasms/ethnology , Liver Neoplasms/virology , Male , Middle Aged , Mutation , Odds Ratio , Risk Factors
12.
PLoS One ; 7(9): e45491, 2012.
Article in English | MEDLINE | ID: mdl-23029049

ABSTRACT

BACKGROUND: The sympathetic neurotransmitter Norepinephrine (NE) contributes to tumorigenesis and cancer progression. This study aims to investigate the role of NE in modulating the immune phenotype and allowing pancreatic carcinoma (PC) cells to escape the immune response. METHODS: Varied concentrations of NE and interferon-gamma (IFN-γ) were administrated to MIA PaCa-2 and BxPC-3 cell lines for 48 hours. Proliferation and invasion were then investigated using an MTT assay and a membrane invasion culture system respectively. MHC-I, B7-1, IDO and B7-H1 expression were measured using real-time quantitative RT-PCR, western blotting and immunocytochemistry. The synergistic and time-dependent effects of NE/IFN-γ were also investigated. Adrenergic antagonists were used to identify the relevant target receptor of NE. RESULTS: The results showed that NE had dose-dependent and time-dependent effects on cell biological processes as well as on the expression of MHC-I, B7-1, IDO and B7-H1. These effects occurred mainly via the ß(2)-adrenergic receptor. Long-term NE treatment was able to antagonize some of the effects of IFN-γ (after 2 weeks of treatment), but NE and IFN-γ had significant synergistic stimulatory effects on IDO and B7-H1 expression. The residual effects on biological activities lasted for 2 weeks, while the immunophenotypic changes decreased at early time points after treatment. CONCLUSIONS: NE plays important roles in modulating PC cell biological activities and affecting MHC-I, B7-1, IDO and B7-H1 expression in vitro, mainly via the ß2-adrenergic receptor (ß2-AR) in a time- and dose-dependent fashion. Only at extended treatment durations could NE affect PC cell progression and immune evasion.


Subject(s)
B7-1 Antigen/genetics , B7-H1 Antigen/genetics , Histocompatibility Antigens Class I/genetics , Indoleamine-Pyrrole 2,3,-Dioxygenase/genetics , Norepinephrine/pharmacology , Pancreatic Neoplasms/genetics , B7-1 Antigen/metabolism , B7-H1 Antigen/metabolism , Cell Line, Tumor , Cell Movement/drug effects , Cell Proliferation/drug effects , Dose-Response Relationship, Drug , Gene Expression Regulation, Neoplastic/drug effects , Histocompatibility Antigens Class I/metabolism , Humans , Indoleamine-Pyrrole 2,3,-Dioxygenase/metabolism , Interferon-gamma/pharmacology , Pancreatic Neoplasms/metabolism , Receptors, Adrenergic/metabolism , Receptors, Interferon/metabolism , Time Factors , Interferon gamma Receptor , Pancreatic Neoplasms
13.
World J Gastroenterol ; 17(21): 2667-73, 2011 Jun 07.
Article in English | MEDLINE | ID: mdl-21677838

ABSTRACT

AIM: To investigate the silencing effects of pAd-shRNA-pleiotrophin (PTN) on PTN in pancreatic cancer cells, and to observe the inhibition of pAd-shRNA-PTN on neurite outgrowth from dorsal root ganglion (DRG) neurons in vitro. METHODS: PAd-shRNA-PTN was used to infect pancreatic cancer BxPC-3 cells; assays were conducted for knockdown of the PTN gene on the 0th, 1st, 3rd, 5th, 7th and 9th d after infection using immunocytochemistry, real-time quantitative polymerase chain reaction (PCR), and Western blotting analysis. The morphologic changes of cultured DRG neurons were observed by mono-culture of DRG neurons and co-culture with BXPC-3 cells in vitro. RESULTS: The real-time quantitative PCR showed that the inhibition rates of PTN mRNA expression in the BxPC-3 cells were 20%, 80%, 50% and 25% on the 1st, 3rd, 5th and 7th d after infection. Immunocytochemistry and Western blotting analysis also revealed the same tendency. In contrast to the control, the DRG neurons co-cultured with the infected BxPC-3 cells shrunk; the number and length of neurites were significantly decreased. CONCLUSION: Efficient and specific knockdown of PTN in pancreatic cancer cells and the reduction in PTN expression resulted in the inhibition of neurite outgrowth from DRG neurons.


Subject(s)
Carrier Proteins/genetics , Carrier Proteins/metabolism , Cytokines/genetics , Cytokines/metabolism , Ganglia, Spinal/cytology , Neurites/physiology , Neurons/metabolism , Pancreatic Neoplasms/metabolism , RNA, Small Interfering/metabolism , Adenoviridae/genetics , Adenoviridae/metabolism , Cells, Cultured , Coculture Techniques , Neurons/cytology , Pancreatic Neoplasms/genetics , RNA, Small Interfering/genetics
14.
Chin Med J (Engl) ; 123(16): 2163-70, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20819658

ABSTRACT

BACKGROUND: Few reports have evaluated the efficacy of re-operation for relapse after initial surgery for hepatocellular carcinoma (HCC) with bile duct thrombosis (BDT). The aim of this study was to investigate the efficacy of initial surgery and subsequent re-operation for HCC with BDT, and their effects on prognosis. METHODS: The clinical data of 880 patients with HCC, including 28 patients with BDT, who underwent radical hepatectomy between 1998 and 2008 in our hospital, were reviewed. The effects of BDT and re-operation on prognosis were retrospectively analyzed. RESULTS: The 1-, 3- and 5-year survival rates were 89.3%, 46.4% and 21.4%, respectively, in 28 patients with BDT versus 91.4%, 52.9% and 20.9% in 852 patients without BDT (P>0.05). Six patients with BDT underwent re-operation after disease relapse, and their survival time was significantly longer than those who did not undergo re-operation (P<0.05). Multivariate analysis indicated that portal vein invasion and tumor size were independently associated with tumor relapse and prognosis (P<0.05). Univariate analysis and multivariate analyses showed that obstructive jaundice was not significantly correlated with tumor relapse or prognosis (P>0.05). CONCLUSIONS: Hepatectomy plus BDT removal is an effective treatment option for HCC with BDT. Obstructive jaundice is not a contraindication for surgery. Re-operation after relapse can provide good outcomes if the cases are appropriately selected.


Subject(s)
Bile Ducts/pathology , Carcinoma, Hepatocellular/surgery , Liver Neoplasms/surgery , Thrombosis/surgery , Adult , Carcinoma, Hepatocellular/diagnostic imaging , Female , Hepatectomy , Humans , Liver Neoplasms/diagnostic imaging , Magnetic Resonance Imaging , Male , Middle Aged , Radiography , Treatment Outcome , Ultrasonography
15.
World J Surg ; 34(5): 1059-65, 2010 May.
Article in English | MEDLINE | ID: mdl-20145927

ABSTRACT

BACKGROUND: Cancer cells develop mechanisms to evade immune cells and achieve progression. Aberrant B7-H1 and B7-1 expressions may help pancreatic carcinoma (PC) cells escape immune attack; these molecules can be considered as prognostic markers for patients with PC who have undergone radical resection. METHODS: We recruited 81 patients who had undergone radical surgical resection for PC between 1999 and 2007. To investigate the prognostic factors, we evaluated the B7-H1 and B7-1 protein expressions in the tissue specimens of these 81 patients by immunohistochemistry and analyzed the clinical and pathological features of these specimens. RESULTS: B7-H1 was expressed mainly in pancreatic islets, and no B7-1 expression was detected in normal pancreatic tissues. B7-H1 and B7-1 expressions were higher in pancreatic carcinoma tissues than in normal pancreatic tissues (P < 0.05). B7-H1 and B7-1 significantly correlated with the pathological grade and tumor-node-metastasis (TNM) stage, respectively (P < 0.05). Furthermore, B7-1-negative or B7-H1-positive statuses were prognostic indicators of poor disease-specific survival (P < 0.05), but only combined B7-1/B7-H1 expression retained the prognostic potential after adjusting by Cox proportional hazards regression models (P < 0.05). CONCLUSIONS: Both B7-H1 and B7-1 are expressed in PC; these molecules are important markers for PC progression. Furthermore, combined B7-1/B7-H1 expression can serve as an independent prognostic marker for PC.


Subject(s)
Antigens, CD/biosynthesis , B7-1 Antigen/biosynthesis , Biomarkers, Tumor/biosynthesis , Pancreatic Neoplasms/immunology , Adult , Aged , B7-H1 Antigen , Female , Humans , Male , Middle Aged , Pancreatectomy , Pancreatic Neoplasms/surgery , Prognosis
16.
Oncol Rep ; 22(4): 825-30, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19724861

ABSTRACT

Active migration and invasion by cancer cells are a prerequisite for the development of metastases. Recent studies have shown that neurotransmitters are involved in the regulation of cancer cell invasion via beta-adrenoceptors (beta-ARs). However, little is known regarding the effect of neurotransmitters on pancreatic cancer cells. The aim of our study was to examine the regulative effect of norepinephrine (NE), which belongs to the group of classical neurotransmitters, on the invasiveness of pancreatic cancer cells and the therapeutic effect of the beta-blocker, propranolol, on them. The human pancreatic cancer cell lines, Miapaca-2 and Bxpc-3, were selected for this study, and in both cell lines, beta1-AR and beta2-AR expression was determined by RT-PCR and Western blotting. The invasiveness of pancreatic cancer cells was examined using the Matrigel invasion assay. The concentrations of MMP-2, MMP-9, and VEGF in the culture medium and in the cancer cells were examined by ELISA and RT-PCR, respectively. We observed that NE promoted the invasiveness of Miapaca-2 cells in a concentration-dependent manner, and NE increased the expression of MMP-2, MMP-9, and VEGF. However, these effects could be inhibited by the beta-blocker, propranolol. In conclusion, the development of metastases is not only genetically determined, but is also influenced by NE, which is one of the signal substances present in the tumor environment. This study also provides experimental evidence for the use of beta-blockers in the chemoprevention of pancreatic cancer metastasis.


Subject(s)
Adrenergic beta-Antagonists/pharmacology , Cell Movement/drug effects , Neoplasm Invasiveness/pathology , Norepinephrine/pharmacology , Pancreatic Neoplasms/pathology , Propranolol/pharmacology , Blotting, Western , Cell Line, Tumor , Enzyme-Linked Immunosorbent Assay , Humans , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase 9/metabolism , Receptors, Adrenergic, beta-1/biosynthesis , Receptors, Adrenergic, beta-2/biosynthesis , Reverse Transcriptase Polymerase Chain Reaction , Vascular Endothelial Growth Factor A/metabolism
17.
Dig Dis Sci ; 54(4): 895-901, 2009 Apr.
Article in English | MEDLINE | ID: mdl-18716876

ABSTRACT

Pleiotrophin (PTN), a heparin-binding growth factor also known as neurite growth-promoting factor, exhibits several properties related with tumor development. PTN and its receptor, N-syndecan, may play a very important role in tumor growth and neural invasion of pancreatic cancer. We investigated PTN and N-syndecan protein levels in 38 patients with pancreatic cancer by immunohistochemistry, and analyzed for its correlation with clinicopathological features, perineural invasion, and prognosis. The results showed that PTN and N-syndecan proteins were found in 24 (63.2%) and 22 (57.9%) specimens, respectively. PTN and N-syndecan expressions were associated with perineural invasion (P = 0.016 and P = 0.029, respectively). High PTN expression was closely related to an advanced TNM stage (P = 0.007), lymph node metastasis (P = 0.040), and decreased postoperative survival at 3 years (50.0% versus 20.8%, respectively; P = 0.001). We conclude that high expression of PTN combined with N-syndecan may contribute to the increased perineural invasion and poor prognosis of pancreatic cancer.


Subject(s)
Biomarkers, Tumor/metabolism , Carcinoma, Pancreatic Ductal/metabolism , Carrier Proteins/metabolism , Cytokines/metabolism , Pancreatic Neoplasms/metabolism , Peripheral Nerves/pathology , Syndecan-3/metabolism , Adult , Aged , Aged, 80 and over , Carcinoma, Pancreatic Ductal/mortality , Carcinoma, Pancreatic Ductal/pathology , Case-Control Studies , Female , Humans , Immunohistochemistry , Male , Middle Aged , Pancreas/innervation , Pancreas/pathology , Pancreatic Neoplasms/mortality , Pancreatic Neoplasms/pathology , Prognosis
18.
Eur J Pharmacol ; 601(1-3): 136-42, 2008 Dec 28.
Article in English | MEDLINE | ID: mdl-18977215

ABSTRACT

To gain insight into the processes by which severe acute pancreatitis induced apoptosis takes place in the liver, and to observe the protective effect of resveratrol on hepatic injury, a rat model of severe acute pancreatitis was induced by administering 4% sodium taurocholate through the common biliopancreatic duct. Pancreatic and hepatic injury was assessed by histology. Serum ALT (alanine aminotransferase), AST (aspartate aminotransferase) and total bilirubin were determined by reaction rate assay, and the serum levels of TNF-alpha (tumor necrosis factor-alpha) and IL-6 (interleukin-6) were detected by ELISA (enzyme linked immunosorbent assay). We investigated cytochrome c released from mitochondria and used the RT-PCR (reverse transcription PCR), Western blot technique to evaluate Bax, Bcl-2, and caspase-3 expression levels in hepatic tissue over the time course of apoptosis. Changes in hepatic cell mitochondrial membrane potential were observed by confocal laser scanning microscopy. The majority of cytochrome c release occurred early in apoptosis from mitochondria, which undergo gradual hepatic impairment. The released cytochrome c can be reduced by resveratrol through both up-regulation of Bcl-2 and down-regulation of Bax and caspase-3. These data provide substantial evidence that apoptosis is involved in hepatic injury during the severe acute pancreatitis process and that resveratrol can ameliorate the situation, thus protecting liver function in rats with severe acute pancreatitis.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Apoptosis/drug effects , Pancreatitis/drug therapy , Stilbenes/pharmacology , Acute Disease , Animals , Caspase 3/drug effects , Caspase 3/metabolism , Cytochromes c/drug effects , Cytochromes c/metabolism , Disease Models, Animal , Gene Expression Regulation/drug effects , Liver/drug effects , Liver/metabolism , Liver/pathology , Male , Mitochondria, Liver/drug effects , Mitochondria, Liver/metabolism , Pancreatitis/physiopathology , Proto-Oncogene Proteins c-bcl-2/drug effects , Proto-Oncogene Proteins c-bcl-2/metabolism , Rats , Rats, Sprague-Dawley , Resveratrol , Severity of Illness Index , bcl-2-Associated X Protein/drug effects , bcl-2-Associated X Protein/metabolism
19.
Nan Fang Yi Ke Da Xue Xue Bao ; 28(7): 1254-8, 2008 Jul.
Article in Chinese | MEDLINE | ID: mdl-18676277

ABSTRACT

OBJECTIVE: To observe the expressions of metastasis-associated protein (S100A4) and matrix metalloproteinase 9 (MMP9) in human non-small cell lung cancer (NSCLC) and investigate their correlations to the infiltration, metastasis and prognosis of NSCLC. METHODS: The expressions of S100A4 and MMP9 were detected in 41 NSCLC specimens and 6 normal lung tissue specimens using immunohistochemistry with SP method. Univariate and multivariate survival analysis were used to analyze the correlations of S100A4 and MMP9 to the clinicopathological characteristics and progrnosis of NSCLC. RESULTS: Compared with normal lung tissues, NSCLC showed significantly increased positivity for S100A4 and MMP9 expression (P<0.05); their expression were significantly higher in adenocarcinoma than in squamous cell carcinoma (P<0.01), and higher in metastatic NSCLC than in that without lymphatic metastasis (P<0.01). The positive expression rates of S100A4 and MMP9 were significantly higher in tumors in TNM stages III +IV than in stages II+I (P<0.05). S100A4 expression was positively correlated to tumor size (P<0.001), while MMP9 was inversely correlated to tumor differentiation (P<0.05). The expressions of S100A4 and MMP9 were both correlated to lymphatic metastasis, TNM stages and pathological types (P<0.05), and they also showed a mutual correlation (P<0.01). Univariate survival analysis confirmed the effects of histological types, lymphatic metastasis, clinical TNM stages and expressions of S100A4 and MMP9 on the survival time of NSCLC patients (P<0.001). Multivariate survival analysis identified clinical TNM stages and expressions of S100A4 and MMP9 as the independent factors affecting the prognosis of NSCLC (P<0.05). CONCLUSION: The expressions of S100A4 and MMP9 are up-regulated in NSCLC and have significant correlations to the clinical and biological behaviors of NSCLC. S100A4 and MMP9 status are independent prognostic predictors of NSCLC, and detection of their expressions may help evaluate the prognosis of NSCLC.


Subject(s)
Carcinoma, Non-Small-Cell Lung/metabolism , Lung Neoplasms/metabolism , Matrix Metalloproteinase 9/biosynthesis , S100 Proteins/biosynthesis , Adult , Aged , Carcinoma, Non-Small-Cell Lung/pathology , Female , Humans , Immunohistochemistry , Kaplan-Meier Estimate , Lung Neoplasms/pathology , Lymphatic Metastasis , Male , Middle Aged , Neoplasm Invasiveness , Prognosis , S100 Calcium-Binding Protein A4
20.
Cancer Biol Ther ; 7(5): 622-7, 2008 May.
Article in English | MEDLINE | ID: mdl-18756622

ABSTRACT

B7-H1 (B7 homologue 1, PD-L1), expressed on the surface of tumor cells or antigen-presenting cells in the tumor microenvironment, can suppress antitumor immune reaction, promote tumor growth and help tumor cells to escape the immune response. To investigate the correlations between B7-H1 expression and acute leukemia patients' immunotherapeutic efficacies and prognoses, we detected the expression of B7-H1 by immunohistochemistry and Real-time quantitative PCR and monitored the immunotherapeutic efficacies and prognosis in 60 acute leukemia patients, in which 14 cases of acute monocyte leukemia(M5) patients received active immunotherapy. The levels of mRNA and protein expression of B7-H1 changed synchronously.B7-H1 was expressed in human acute leukemia cells, especially in M5. The expressions of B7-H1 were significantly higher in the relapse patients than in the de novo patients and after immunotherapy than before immunotherapy. Significant correlations existed between the expressions of B7-H1 and the M5 patients' immunological reactions and immunotherapeutic efficacies.B7-H1 negative patients had better immunotherapeutic efficacies than the positive patients who were prone to have a severe complication of pulmonary infection. Multivariate analysis indicated that B7-H1 status was an independent prognostic factor for M5 patients. In conclusion, B7-H1 is highly expressed on leukemia cells of M5 patients, can significantly affect the immunotherapeutic efficacies of M5 patients and is a novel prognostic marker for M5.


Subject(s)
Antigens, CD/biosynthesis , Gene Expression Regulation, Leukemic , Leukemia/metabolism , Adolescent , Adult , Aged , B7-H1 Antigen , Cell Line, Tumor , Child , Female , Humans , Immunotherapy/methods , Male , Middle Aged , Prognosis , Remission Induction
SELECTION OF CITATIONS
SEARCH DETAIL